Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

PLoS One. 2012;7(4):e35976. doi: 10.1371/journal.pone.0035976. Epub 2012 Apr 27. Erratum in: PLoS One. 2012;7(7): doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac.

2.

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

Cancer Res. 2011 Sep 15;71(18):6019-29. doi: 10.1158/0008-5472.CAN-11-1417. Epub 2011 Jul 28.

3.

Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR.

Cancer. 2011 Sep 1;117(17):4049-59. doi: 10.1002/cncr.26004. Epub 2011 Mar 1.

4.

CENP-E checks in microtubule-drug resistance.

Chanel-Vos C, Giannakakou P.

Cell Cycle. 2010 Apr 15;9(8):1456. Epub 2010 Apr 15. No abstract available.

PMID:
20421712
5.

Alphavirus Entry and Membrane Fusion.

Kielian M, Chanel-Vos C, Liao M.

Viruses. 2010 Mar 26;2(4):796-825.

Supplemental Content

Loading ...
Support Center